Tech Company Financing Transactions
mbiomics Funding Round
mbiomics closed a $14 million Series A venture capital round on 3/23/2023. Investors included MIG Group, Bayern Kapital and High-Tech Gründerfonds.
Transaction Overview
Company Name
Announced On
3/23/2023
Transaction Type
Venture Equity
Amount
$14,017,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to embark on strategic partnerships, expand its Munich laboratory facilities and R&D teams in Germany, and potentially increase US activities.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Kistlerhofstr. 70 Building 79
Munich, 81379
DE
Munich, 81379
DE
Phone
Website
Email Address
Overview
mbiomics offers a unique combination of fast, quantitative and accurate analysis of the microbiome. mbiomics is a pioneer in targeted microbiome profiling. Our patented precision technology enables unparalleled quantitative resolution and drastically faster microbiome analysis. This creates a basis for various future clinical applications and it will accelerate microbiome-based therapeutics development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Laura Figulla
Co-Founder
Heinrich Grabmayr
Co-Founder
Markus Rinecker
Co-Founder
Johannes Woehrstein
Browse more venture capital transactions:
Prev: 3/22/2023: Gilead Sciences venture capital transaction
Next: 3/23/2023: True Botanicals venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to record every notable VC transaction. VC transactions reported here are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs